Bristol-Myers Squibb PFD... (BMYMP)
Bristol-Myers Squibb PFD CONV 2 Statistics
Share Statistics
Bristol-Myers Squibb PFD CONV 2 has - shares outstanding. The number of shares has increased by 30.15% in one year.
| Shares Outstanding | - |
| Shares Change (YoY) | 30.15% |
| Shares Change (QoQ) | 6.95% |
| Owned by Institutions (%) | n/a |
| Shares Floating | 132.75M |
| Failed to Deliver (FTD) Shares | - |
| FTD / Avg. Volume | < 0.01% |
Short Selling Information
| Short Interest | n/a |
| Short % of Shares Out | n/a |
| Short % of Float | n/a |
| Short Ratio (days to cover) | n/a |
Valuation Ratios
The PE ratio is -14.72 and the forward PE ratio is null. Bristol-Myers Squibb PFD CONV 2's PEG ratio is 0.07.
| PE Ratio | -14.72 |
| Forward PE | n/a |
| PS Ratio | 2.73 |
| Forward PS | null |
| PB Ratio | 8.06 |
| P/FCF Ratio | 9.44 |
| PEG Ratio | 0.07 |
Enterprise Valuation
Currently the Enterprise Value (EV) is not available for Bristol-Myers Squibb PFD CONV 2.
| EV / Sales | n/a |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | n/a |
Financial Position
The company has a current ratio of 1.25, with a Debt / Equity ratio of 3.13.
| Current Ratio | 1.25 |
| Quick Ratio | 1.15 |
| Debt / Equity | 3.13 |
| Debt / EBITDA | 16.16 |
| Debt / FCF | 3.67 |
| Interest Coverage | 3.02 |
Financial Efficiency
Return on Equity is n/a and Return on Invested Capital is n/a.
| Return on Equity | n/a |
| Return on Assets | n/a |
| Return on Invested Capital | n/a |
| Revenue Per Employee | $- |
| Profits Per Employee | $- |
| Employee Count | undefined |
| Asset Turnover | 0.52 |
| Inventory Turnover | 5.46 |
Taxes
| Income Tax | 554M |
| Effective Tax Rate | -6.61% |
Stock Price Statistics
The stock price has increased by 9.38% in the last 52 weeks. The beta is 0.2, so Bristol-Myers Squibb PFD CONV 2's price volatility has been higher than the market average.
| Beta | 0.2 |
| 52-Week Price Change | 9.38% |
| 50-Day Moving Average | 940.21 |
| 200-Day Moving Average | 897.65 |
| Relative Strength Index (RSI) | 14.88 |
| Average Volume (20 Days) | 1 |
Income Statement
In the last 12 months, Bristol-Myers Squibb PFD CONV 2 had revenue of 48.3B and earned -8.95B in profits. Earnings per share was -67.88.
| Revenue | 48.3B |
| Gross Profit | 34.33B |
| Operating Income | 5.89B |
| Net Income | -8.95B |
| EBITDA | 3.17B |
| EBIT | -6.43B |
| Earnings Per Share (EPS) | -67.88 |
Balance Sheet
The company has 10.35B in cash and 51.2B in debt, giving a net cash position of -40.85B.
| Cash & Cash Equivalents | 10.35B |
| Total Debt | 51.2B |
| Net Cash | -40.85B |
| Retained Earnings | 14.91B |
| Total Assets | - |
| Working Capital | - |
Cash Flow
In the last 12 months, operating cash flow was 15.19B and capital expenditures -1.25B, giving a free cash flow of 13.94B.
| Operating Cash Flow | 15.19B |
| Capital Expenditures | -1.25B |
| Free Cash Flow | 13.94B |
| FCF Per Share | 105.77 |
Margins
Gross margin is 71.08%, with operating and profit margins of 12.19% and -18.53%.
| Gross Margin | 71.08% |
| Operating Margin | 12.19% |
| Pretax Margin | -17.35% |
| Profit Margin | -18.53% |
| EBITDA Margin | 6.56% |
| EBIT Margin | 12.19% |
| FCF Margin | 28.87% |
Dividends & Yields
BMYMP does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Payout Ratio | n/a |
| Earnings Yield | n/a |
| FCF Yield | n/a |
Analyst Forecast
Currently there are no analyst rating for BMYMP.
| Price Target | n/a |
| Price Target Difference | n/a |
| Analyst Consensus | n/a |
| Analyst Count | n/a |
Scores
| Altman Z-Score | null |
| Piotroski F-Score | null |